These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33911135)

  • 21. Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.
    Kummer LYL; Fernández Blanco L; Kreher C; Bos A; Kuijper LH; Verstegen NJM; van de Sandt CE; Konijn VAL; Duurland MC; Menage C; Jorritsma T; Steenhuis M; Hagen RR; van den Dijssel J; de Jongh R; Ashhurst T; van Gils MJ; Garcia-Vallejo JJ; Claireaux M; Stalman EW; van Dam KPJ; Wieske L; Boekel L; Wolbink G; Tas SW; Rispens T; Kuijpers TW; Eftimov F; van Ham SM; Ten Brinke A;
    RMD Open; 2024 Oct; 10(4):. PubMed ID: 39375177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis.
    Subesinghe S; Bechman K; Rutherford AI; Goldblatt D; Galloway JB
    J Rheumatol; 2018 Jun; 45(6):733-744. PubMed ID: 29545454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
    Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK; Lee YJ; Shin K; Ha YJ; Lee EY; Song YW; Choi Y; Winthrop KL; Lee EB
    Ann Rheum Dis; 2018 Jun; 77(6):898-904. PubMed ID: 29572291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Slauenwhite D; McAlpine SM; Hanly JG; Malik A; Haidl ID; Marshall JS; Issekutz TB
    Arthritis Rheumatol; 2020 Jul; 72(7):1091-1102. PubMed ID: 32039570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK; Lee MA; Lee EY; Song YW; Choi Y; Winthrop KL; Lee EB
    Ann Rheum Dis; 2017 Sep; 76(9):1559-1565. PubMed ID: 28468794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.
    Ortqvist A; Henckaerts I; Hedlund J; Poolman J
    Vaccine; 2007 Mar; 25(13):2445-50. PubMed ID: 17052816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.
    Nived P; Nagel J; Saxne T; Geborek P; Jönsson G; Skattum L; Kapetanovic MC
    Vaccine; 2017 Jun; 35(29):3639-3646. PubMed ID: 28552512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL; Kivitz AJ; Birbara C; Luo AY
    J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.
    Nagel J; Geborek P; Saxne T; Jönsson G; Englund M; Petersson IF; Nilsson JÅ; Truedsson L; Kapetanovic MC
    Arthritis Res Ther; 2015 May; 17(1):124. PubMed ID: 25986458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment.
    Nived P; Saxne T; Geborek P; Mandl T; Skattum L; Kapetanovic MC
    BMC Rheumatol; 2018; 2():12. PubMed ID: 30886963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.